



**Friedemann Weber**

**Kontakt**

Friedemann Weber

## Publikationen (16)

van den Worm S, Thiel V, Snijder E, Siddell S, Chang G, Dijkman R, Kuri T, Züst R, Weber F, Zevenhoven J, Eriksson K, Davidson A. Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination. *PLoS one* 2012; 7:e32857.

Pfefferle S, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel H, Schwegmann-Weßels C, Pöhlmann S, Haas J, Drosten C, Pumpor K, Züst R, Schöpf J, Kögl M, Friedel C, Müller M, Carbajo-Lozoya J, Stellberger T, von Dall'armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, von Brunn A. The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors. *PLoS Pathog* 2011; 7:e1002331.

Kuri T, Ziebuhr J, Thiel V, Siddell S, Davidson A, Snijder E, Züst R, Putics A, Eriksson K, Weber F. The ADP-ribose-1''-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses. *J Gen Virol* 2011; 92:1899-905.

Pichlmair A, Habjan M, Unger H, Weber F. Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. *Vector Borne Zoonotic Dis* 2010; 10:701-3.

Gori Savellini G, Weber F, Terrosi C, Habjan M, Martorelli B, Cusi M. Toscana virus induces interferon although its NSs protein reveals antagonistic activity. *J Gen Virol* 2010; 92:71-9.

Kuri T, Habjan M, Penski N, Weber F. Species-independent bioassay for sensitive quantification of antiviral type I interferons. *Virology* 2010; 7:50.

Kuri T, Zhang X, Habjan M, Martínez-Sobrido L, García-Sastre A, Yuan Z, Weber F. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. *J Gen Virol* 2009; 90:2686-94.

Habjan M, Pichlmair A, Elliott R, Overby A, Glatter T, Gstaiger M, Superti-Furga G, Unger H, Weber F. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. *J Virol* 2009; 83:4365-75.

Näslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, Weber F, Bucht G. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. *Virology* 2009; 385:409-15.

Habjan M, Penski N, Wagner V, Spiegel M, Overby A, Kochs G, Huiskonen J, Weber F. Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses. *Virology* 2009; 385:400-8.

Habjan M, Penski N, Spiegel M, Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. *J Gen Virol* 2008; 89:2157-66.

Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. *Cytokine & growth factor reviews* 2008; 19:121-32.

Habjan M, Mirazimi A, Mühlberger E, Schneider U, Pichlmair A, Wagner V, Zimmermann P, Martin A, Schumann M, Klingström J, Andersson I, Weber F. Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. *PLoS one* 2008; 3:e2032.

Züst R, Cervantes-Barragan L, Kuri T, Blakqori G, Weber F, Ludewig B, Thiel V. Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. *PLoS pathogens* 2007; 10;3(8):e109:1062-1072.

Blakqori G, Staeheli P, Michiels T, Weiss S, Kalinke U, Kohl A, Fragkoudis R, Attarzadeh-Yazdi G, Olson K, Sánchez-Vargas I, Blair C, Habjan M, Delhaye S, Weber F. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. *J Virol* 2007; 81:4991-9.

Cervantes-Barragan L, Züst R, Weber F, Spiegel M, Lang K, Akira S, Thiel V, Ludewig B. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. *Blood* 2007; 109:1131-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)